News & Updates

Poor mental health raises risk of incident T2D
Poor mental health raises risk of incident T2D
18 Aug 2022

People with worse overall psychological wellbeing are at significantly higher risk of developing type 2 diabetes (T2D) in a dose‒response manner irrespective of their genetic predisposition, suggest the results of a recent study.

Poor mental health raises risk of incident T2D
18 Aug 2022
Counseling intervention helps avert weight gain in midlife women
Counseling intervention helps avert weight gain in midlife women
15 Aug 2022

Women who are trying to prevent obesity during midlife may benefit from counseling interventions, which a recent study has shown to result in modest differences in weight change without causing any significant harm.

Counseling intervention helps avert weight gain in midlife women
15 Aug 2022
Variations in ambulant glucose tied to severe hypoglycaemia, unawareness of episode in T1D
Variations in ambulant glucose tied to severe hypoglycaemia, unawareness of episode in T1D
12 Aug 2022

In patients with type 1 diabetes (T1D), the coefficient of variation (CV) of ambulant glucose levels appears to be correlated with severe hypoglycaemia episodes and unawareness of hypoglycaemia, a recent Japan study has found.

Variations in ambulant glucose tied to severe hypoglycaemia, unawareness of episode in T1D
12 Aug 2022
Diabetes, prediabetes may signal disability in middle-aged adults
Diabetes, prediabetes may signal disability in middle-aged adults
11 Aug 2022

The presence of diabetes or prediabetes appears to worsen the risk of disability and mortality, reports a recent Japan study.

Diabetes, prediabetes may signal disability in middle-aged adults
11 Aug 2022
Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD
Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD
11 Aug 2022

In patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD), treatment with canagliflozin safely decreases the risk of developing end-stage renal disease, reports a new Japan study.

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD
11 Aug 2022